TG Therapeutics announces issuance of additional patents for BRIUMVI

TG Therapeutics announced the issuance of three additional patents by the United States Patent and Trademark Office, USPTO, for BRIUMVI, the first and only anti-CD20 monoclonal antibody approved in the US for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion following the starting dose. The additional recently issued patents, US Patent Nos. 11,807,689; 11,814,439; and 11,884,740, leverage the unique glycoprofile of ublituximab to extend patent protection covering the composition of matter of ublituximab and methods of treatment utilizing ublituximab into 2042. Michael Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “We are pleased to announce the issuance of these additional patents for BRIUMVI which add to our existing patent portfolio, and extend patent protection through 2042. Life cycle management is of the utmost importance, and we believe these additional patents will provide a long runway to continue to explore the full potential of BRIUMVI, including expanding the potential reach of BRIUMVI in multiple sclerosis as well as in other autoimmune indications.”